Marcelo A S de Toledo
Overview
Explore the profile of Marcelo A S de Toledo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Automated CRISPR/Cas9-based genome editing of human pluripotent stem cells using the StemCellFactory
Niessing B, Breitkreuz Y, Elanzew A, de Toledo M, Vajs P, Nolden M, et al.
Front Bioeng Biotechnol
. 2024 Oct;
12:1459273.
PMID: 39372431
CRISPR/Cas9 genome editing is a rapidly advancing technology that has the potential to accelerate research and development in a variety of fields. However, manual genome editing processes suffer from limitations...
2.
Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, et al.
Cancer Res
. 2024 Jun;
84(18):2985-3003.
PMID: 38885318
Increasing evidence supports the interplay between oncogenic mutations and immune escape mechanisms. Strategies to counteract the immune escape mediated by oncogenic signaling could provide improved therapeutic options for patients with...
3.
Flosdorf N, Bohnke J, de Toledo M, Lutterbach N, Lerma V, Grasshoff M, et al.
Stem Cell Reports
. 2024 Jan;
19(2):224-238.
PMID: 38278152
The myeloproliferative disease polycythemia vera (PV) driven by the JAK2 V617F mutation can transform into myelofibrosis (post-PV-MF). It remains an open question how JAK2 V617F in hematopoietic stem cells induces...
4.
Olschok K, Altenburg B, de Toledo M, Maurer A, Abels A, Beier F, et al.
Front Oncol
. 2023 Nov;
13:1277453.
PMID: 37941547
Imetelstat shows activity in patients with myeloproliferative neoplasms, including primary myelofibrosis (PMF) and essential thrombocythemia. Here, we describe a case of prolonged disease stabilization by imetelstat treatment of a high-risk...
5.
Vieri M, Tharmapalan V, Kalmer M, Baumeister J, Nikolic M, Schnitker M, et al.
Blood Cancer J
. 2023 Nov;
13(1):164.
PMID: 37926720
No abstract available.
6.
de Toledo M, Fu X, Maie T, Buhl E, Gotz K, Schmitz S, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982353
Mast cells (MCs) represent a population of hematopoietic cells with a key role in innate and adaptive immunity and are well known for their detrimental role in allergic responses. Yet,...
7.
Xu H, Li Z, Kuo C, Gotz K, Look T, de Toledo M, et al.
Elife
. 2023 Mar;
12.
PMID: 36916882
Transcription factors play a determining role in lineage commitment and cell differentiation. Interferon regulatory factor 8 (IRF8) is a lineage determining transcription factor in hematopoiesis and master regulator of dendritic...
8.
de Toledo M, Fu X, Kluge F, Gotz K, Schmitz S, Wanek P, et al.
Stem Cell Res
. 2022 Mar;
60:102732.
PMID: 35279545
The receptor tyrosine kinase c-KIT (CD117) has a key role in hematopoiesis and is a marker for endothelial and cardiac progenitor cells. In vivo, deficiency of c-KIT is lethal and...
9.
Bernardo M, da Silva B, Hamouda A, de Toledo M, Schalla C, Rutten S, et al.
Sci Rep
. 2022 Feb;
12(1):2333.
PMID: 35149687
Bone defects stand out as one of the greatest challenges of reconstructive surgery. Fused deposition modelling (FDM) allows for the printing of 3D scaffolds tailored to the morphology and size...
10.
Olschok K, Han L, de Toledo M, Bohnke J, Grasshoff M, Costa I, et al.
Stem Cell Reports
. 2021 Oct;
16(11):2768-2783.
PMID: 34678208
Calreticulin (CALR) mutations are driver mutations in myeloproliferative neoplasms (MPNs), leading to activation of the thrombopoietin receptor and causing abnormal megakaryopoiesis. Here, we generated patient-derived CALRins5- or CALRdel52-positive induced pluripotent...